Six Cycles of Doxorubicin and Cyclophosphamide or Paclitaxel Are Not Superior to Four Cycles As Adjuvant Chemotherapy for Breast Cancer in Women With Zero to Three Positive Axillary Nodes: Cancer and Leukemia Group B 40101

PURPOSE: The ideal duration of adjuvant chemotherapy for patients with lower risk primary breast cancer is not known. Cancer and Leukemia Group B trial 40101 was conducted using a phase III factorial design to define whether six cycles of a chemotherapy regimen are superior to four cycles. We also s...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Shulman, Lawrence N., Cirrincione, Constance T., Berry, Donald A., Becker, Heather P., Perez, Edith A., O'Regan, Ruth, Martino, Silvana, Atkins, James N., Mayer, Erica, Schneider, Charles J., Kimmick, Gretchen, Norton, Larry, Muss, Hyman, Winer, Eric P., Hudis, Clifford
Format: Artigo
Langue:Inglês
Publié: American Society of Clinical Oncology 2012
Sujets:
ORIGINAL REPORTS
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3494835/
https://ncbi.nlm.nih.gov/pubmed/22826271
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.6405
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires